Phosphorothioate-Conjugated miRNAs for Specialized Applications

Adaptation of phosphorothioate-conjugated miRNAs for treating multiple myeloma and inhibiting IL-6 signaling in high-security, disaster relief, extreme weather, and remote or isolated environments.

The original patent disclosed phosphorothioate-conjugated miRNAs for treating multiple myeloma and inhibiting IL-6 signaling. However, these miRNAs may not be effective in specialized environments such as high-security facilities, disaster relief settings, extreme weather conditions, or remote or isolated areas. The new inventive concept addresses these limitations by adapting the miRNAs to be resistant to degradation, portable, and able to withstand temperature fluctuations, making them suitable for use in these specialized environments.

The new inventive concept involves modifying the phosphorothioate-conjugated miRNAs to be resistant to degradation by environmental stressors, such as high temperatures, humidity, and radiation. This is achieved by using specialized packaging materials, such as self-contained, single-use delivery devices, and formulating the miRNAs to withstand temperature fluctuations. Additionally, the miRNAs can be designed to be portable and operate in low-resource environments, making them suitable for use in disaster relief settings. The inventive concept also includes a system for monitoring the efficacy of the miRNAs in high-security environments, using encrypted and secure sensors capable of detecting the presence or activity of the miRNAs.

The new inventive concept is novel and non-obvious because it adapts the phosphorothioate-conjugated miRNAs for use in specialized environments, which was not disclosed in the original patent. The inventive step lies in the modification of the miRNAs to be resistant to degradation, portable, and able to withstand temperature fluctuations, making them suitable for use in high-security, disaster relief, extreme weather, and remote or isolated environments.

Alternative embodiments of the inventive concept could include using different types of miRNAs, such as siRNAs or shRNAs, or modifying the phosphorothioate moiety to be more resistant to degradation. Additionally, the inventive concept could be adapted for use in other specialized environments, such as space exploration or military operations.

The inventive concept has potential commercial applications in the treatment of multiple myeloma and inhibition of IL-6 signaling in high-security, disaster relief, extreme weather, and remote or isolated environments. The target market includes pharmaceutical companies, biotechnology companies, and government agencies involved in disaster relief and national security.